<DOC>
	<DOCNO>NCT02653105</DOCNO>
	<brief_summary>Does olfactomédine provide help limit number false positives overall image balance limit number unnecessary biopsy ?</brief_summary>
	<brief_title>Women Risk Breast Cancer OLFM4</brief_title>
	<detailed_description>About 5 % breast cancer associate presence constitutional genetic alteration . Two gene study : BRCA1 BRCA2 . The national program breast cancer screen target woman 50 74 year include woman significant risk factor . However identifiable risk situation , breast cancer incidence increase : affect 1 4 woman certain risk histological lesion 1 2 woman carry mutation BRCA1 BRCA2 gene . Studies show olfactomédine 4 ( OLFM4 ) highly overexpressed tumor compare healthy tissue . The OLFM4 might therefore marker early detection breast cancer . We wish determine positive predictive value OLFM4 seric dosing patient risk respect imaging .</detailed_description>
	<mesh_term>Hereditary Breast Ovarian Cancer Syndrome</mesh_term>
	<criteria>Age &gt; = 18 year High risk woman breast cancer occurrence define follow criterion : Women carry genetic mutation BRCA1 2 TP53 , enter already screen breast IRM Women high probability hereditary predisposition breast cancer ( 20 % risk 70 year breast cancer BOADICEA model ) , assessed oncogeneticists Information person signing inform consent Women history breast cancer situ Person affiliate social security scheme beneficiary regime</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>High risk cancer , BRCA1 2 mutation , Olfactomedine 4</keyword>
</DOC>